Skip to main content
. 2010 Jan 15;10:18. doi: 10.1186/1471-2407-10-18

Table 3.

Percentages of patients showing positive immunohistochemical reactions to p-ELK-1, ATF-2 [31], p50 and p65 [5] in normal prostate (NP), benign prostatic hyperplasia (BPH) and prostatic carcinoma (PC) and average optical densities of immunostaining in positive patients.

p-ELK-1 p-ATF-2 p50 p65
Prostates (no.) Positive cases (%) Optical density Positive cases (%) Optical density Positive cases (%) Optical density Positive cases (%) Optical density

Normal (20) 100 2.41 ± 0.9a 100 3.34 ± 0.83a 60 7.88 ± 2.4* 0

BPH (35)
 Cytoplasm 14.28 9.42 ± 5.13* 100 18.6 ± 1.72# 71.4 9.08 ± 3.23*
 Nucleus 82.85 10.52 ± 2.56b 45.71 5.25 ± 2.16a

PIN
 Low grade PIN (12) 100 3.22 ± 0.7a 100 4.32 ± 1.09* 58.3 15.32 ± 2.00# 0
 High grade PIN (15)
  Cytoplasm 60 17.35 ± 1.45# 53.3 13.35 ± 1.78# 86.6 27.51 ± 2.79§ 93.3 30.17 ± 3.08#
  Nucleus 40 18.27 ± 2.31c 26.6 12.31 ± 4.21b 26.6 28.76 ± 3.31a 13.3 29.77 ± 2.13a

PC
 Low Gleason (21)
  Cytoplasm 66.6 19.62 ± 5.64# 61.9 12.68 ± 3.28# 80.9 28.01 ± 2.25§ 100 23.8 ± 2.93§
  Nucleus 42.85 18.65 ± 3.4c 23.8 10.58 ± 1.2b 30.1 32.08 ± 2.96a 19 28.34 ± 2.04a
 Medium Gleason (51)
  Cytoplasm 72.54 17.75 ± 4.54# 68.62 11.75 ± 3.45# 94.1 29.17 ± 1.22§ 92.1 29.09 ± 1.90#
  Nucleus 37.25 17.23 ± 3.56c 19.6 9.56 ± 3.87b 41.2 33.82 ± 4.07a 45.1 34.91 ± 4.32b
 High Gleason (21)
  Cytoplasm 85.71 19.76 ± 4.78# 76.19 12.98 ± 5.11# 100 39.37 ± 4.15¥ 80.9 36.71 ± 2.18¥
  Nucleus 33.3 18.76 ± 3.87c 14.28 13.43 ± 3.56b 47.6 41.26 ± 2.31b 71.4 46.56 ± 1.20c

Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Statistical analysis also separated cytoplasmic (symbol superscripts) and nuclear (letter superscripts) values. Values denoted by different superscripts are significantly different from each other. Significance was determined by the one way ANOVA test at p ≤ 0.05, by multiple pairwise comparisons (GraphPad PRISMA 3.0 computer program).

HHS Vulnerability Disclosure